Trump Proposes 25% Tariff on Auto, Pharma, and Semiconductor Imports: Implications for India
United States President Donald Trump has announced his intent to impose a 25% tariff on imports of automobiles, semiconductors, and pharmaceutical products, with a formal declaration expected by April 2.
This development signals a major escalation in the U.S. trade war, potentially disrupting global supply chains and trade dynamics.
Previously, the U.S. administration had levied a 25% tariff on steel and a 10% duty on aluminum imports, which are slated to come into effect in March. Speaking at his Mar-a-Lago resort, President Trump revealed that the new tariffs could start at 25% and increase further over the next year. “I probably will tell you that on April 2, but it’ll be in the neighborhood of 25%,” Trump stated. On pharmaceuticals and semiconductor chips, he added, “It’ll be 25% and higher, and it’ll go very substantially higher over a course of a year.”
He emphasized that companies would be allowed time to set up manufacturing within the U.S. to avoid the new duties. “When they come into the United States and they have their plant or factory here there is no tariff, so we want to give them a little bit of a chance,” Trump said, according to a report by the Financial Post.
Economists have warned that such tariffs could lead to higher consumer prices in the U.S., potentially aggravating inflation. Trump also proposed “reciprocal” tariffs on a country-by-country basis, though specific guidelines are yet to be finalized.
Impact on India’s Pharmaceutical Sector
India, a major global supplier of generic medicines, could face serious consequences if the proposed tariffs are implemented. The United States is the largest importer of Indian pharmaceutical products. According to Pharmexcil (Pharmaceuticals Export Promotion Council of India), Indian pharma exports to the U.S. reached $8.73 billion in FY2024, accounting for nearly 31% of India’s total pharma exports.
Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA), responded to the development, highlighting India’s critical role in supplying affordable medications to the U.S. “The Indian pharmaceutical industry plays a vital role in ensuring access to affordable, quality-assured medicines in the U.S., supplying nearly 47% of generic drugs used by American patients,” Jain told Financial Express.
He emphasized that the proposed reciprocal tariffs are still under discussion and will be addressed through bilateral diplomatic channels. “We are confident that continuous dialogue will help both nations maintain access to essential medicines. Ensuring availability of affordable drugs is a mutual priority,” he added.
Jain also underlined the long-standing healthcare collaboration between India and the U.S.
Market Reaction & Company Exposure
Following Trump’s announcement, the Nifty Pharma index dropped by up to 10%, as investors reacted to potential revenue risks for Indian drugmakers. Large companies such as Dr. Reddy’s Laboratories, Sun Pharma, and Cipla saw sharp declines in their stock prices.
Experts note that Indian pharmaceutical firms are more exposed to the tariff threat than automakers, given the significant volume of exports to the U.S. While automobile exports from India to the U.S. account for just 0.2%, over 38% of India’s pharma exports are U.S.-bound, according to SBI Research.
A News18 report citing Nomura suggests that earnings for Indian drugmakers like Dr. Reddy’s, Lupin, and Cipla could decline by 6.5% in FY26 if the tariffs are imposed. On the other hand, companies like Sun Pharma and Torrent Pharma may experience limited impact due to lower dependence on U.S. generics sales.
Industry Perspective
Commenting on the development, Hari Kiran Chereddi, Managing Director of HRV Global Life Sciences & CEO of New Horizon Global Pharma, said:
“The proposed 25% duty on pharmaceutical imports into the U.S. reflects shifting dynamics in global trade. While it poses challenges, it also opens opportunities for Indian drugmakers to innovate and reinforce their leadership in providing cost-effective, high-quality medicines.”
